Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from China Medical System Holdings ( (HK:0867) ).
China Medical System Holdings reported that all resolutions at its 23 April 2026 annual general meeting were approved by poll, with the full issued share capital of 2,439,528,512 shares eligible to vote and no restrictions on shareholder participation. All directors attended in person or electronically, and Computershare Hong Kong Investor Services acted as scrutineer.
Shareholders adopted the 2025 audited accounts, approved a final dividend of RMB0.1366 per share, re-elected two directors and authorised the board to set directors’ pay and reappoint Deloitte as auditor. Mandates to issue new shares, repurchase shares and extend the issuance mandate by the amount repurchased were also passed, reinforcing the board’s financial flexibility and capital-management tools for the coming year.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$16.80 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a pharmaceutical company listed in Hong Kong and Singapore, focused on developing, marketing and distributing prescription drugs in China. The group operates through a networked commercial platform, targeting both hospital and primary-care markets with a portfolio of specialty and generic medicines.
Average Trading Volume: 4,568,240
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$33.79B
See more data about 0867 stock on TipRanks’ Stock Analysis page.